Printer Friendly

CYTOCARE, INC. REPORTS YEAR-END RESULTS

CYTOCARE, INC. REPORTS YEAR-END RESULTS
 IRVINE, Calif., Feb. 14 /PRNewswire/ -- Cytocare, Inc. (NASDAQ: CYTI), today reported a net income of $862,000, or $.18 per share ($.17 fully diluted), for the year ended Dec. 31, 1991, on revenues of $9,775,000.
 This compares with a net loss of $5,103,000, or $1.09 loss per share, for the year ended Dec. 31, 1990, on revenues of $11,688,000. For the three months ended Dec. 31, 1991, the net income was $138,000, or $.03 per share on revenues of $2,391,000, compared to a net loss of $1,415,000, or $.30 loss per share on revenues of $3,092,000, for the same period in 1990.
 Cytocare serves urology with biochemical research in prostate diagnostics and therapeutics, and provides kidney stone lithotripsy through its manufacturing subsidiary, Medstone International, Inc.
 CYTOCARE, INC.
 Condensed Comparative Operating Results
 Period Ended Three Months Year
 Dec. 31 1991 1990 1991 1990
 Revenues $2,391,000 $3,092,000 $9,775,000 $11,688,000
 Inc. (loss) bef. taxes
 & extraord. credit 151,000 (1,415,000) 963,000 (5,597,000)
 Net income (loss) 138,000 (1,415,000) 862,000 (5,103,000)
 Earnings (loss) per share:
 Primary $.03 $(.30) $.18 $(1.09)
 Fully diluted $.03 -- $.17 --
 Number of shares used
 in the computation of
 income/loss per share:
 Primary 4,930,449 4,703,263 4,922,664 4,671,321
 Fully diluted 4,941,313 -- 4,949,320 --
 -0- 2/14/92
 CONTACT: Jeannine Cormane of Cytocare, 714-587-0500, ext. 345
 (CYTI)
CO: CYTOCARE, INC.
IN: MTC
SU: ERN
ST: CALIFORNIA (CA)


-- LA004 -- 9072 02/14/92
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 14, 1992
Words:278
Previous Article:PREMIER BOB RAE APPOINTS ACTING MINISTER OF ENERGY
Next Article:FEDERAL AGENTS CRACK DOWN ON WALRUS HEADHUNTERS, DRUGS-FOR-IVORY DEALERS
Topics:


Related Articles
CYTOCARE BUYS RIGHTS TO PROSTATE CANCER ANTIBODIES
CYTOCARE REPORTS FIRST QUARTER RESULTS
CYTOCARE ANNOUNCES LITIGATION VICTORY
CYTOCARE INC. ELECTS NEW DIRECTOR
CYTOCARE FILES 510(k) SUBMISSION FOR LASER CATHETER FOR LASER SURGERY OF UROLOGICAL TISSUES
Primus Innovations and Health Robotics Launch Strategic Partnership to Accelerate Transformation in Chemotherapy Compounding.
CytoCare Showcased on CBS News Nationally and CBS Affiliates.
Health Robotics Announces Strategic Partnership in Japan for its CytoCare(TM) Robot with TOSHO Inc.
Health Robotics Announces Strategic Partnership in Japan for its CytoCare(TM) Robot with TOSHO Inc.
ICU Medical Inc. and Health Robotics Announce Compatibility of CytoCare(TM) Robot and CLAVE(R) Needle-Free Connector to Enable Safer Hazardous Drug...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters